RT Journal Article SR Electronic T1 Cerebral Histamine H1 Receptor Binding Potential Measured with PET Under a Test Dose of Olopatadine, an Antihistamine, Is Reduced After Repeated Administration of Olopatadine JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 887 OP 892 DO 10.2967/jnumed.108.058537 VO 50 IS 6 A1 Michio Senda A1 Nobuo Kubo A1 Kazuhiko Adachi A1 Yasuhiko Ikari A1 Keiichi Matsumoto A1 Keiji Shimizu A1 Hideyuki Tominaga YR 2009 UL http://jnm.snmjournals.org/content/50/6/887.abstract AB Some antihistamine drugs that are used for rhinitis and pollinosis have a sedative effect as they enter the brain and block the H1 receptor, potentially causing serious accidents. Receptor occupancy has been measured with PET under single-dose administration in humans to classify antihistamines as more sedating or as less sedating (or nonsedating). In this study, the effect of repeated administration of olopatadine, an antihistamine, on the cerebral H1 receptor was measured with PET. Methods: A total of 17 young men with rhinitis underwent dynamic brain PET with 11C-doxepin at baseline, under an initial single dose of 5 mg of olopatadine (acute scan), and under another 5-mg dose after repeated administration of olopatadine at 10 mg/d for 4 wk (chronic scan). The H1 receptor binding potential was estimated using Logan graphical analysis with cerebellum as reference region input. Results: The acute scan showed a slight decrease in H1 receptor binding potential across the cerebral cortex (by 15% in the frontal cortex), but the chronic scan showed a marked decrease (by 45% from the acute scan in the frontal cortex). Behavioral data before and after the PET scans did not reveal any sedative effect. Conclusion: The results may be interpreted as either intracerebral accumulation of olopatadine or H1 receptor downregulation due to repeated administration. The study shows feasibility and potential value for PET in evaluating the pharmacologic effect of a drug not only after a single dose but also after repeated administration.